BCYC logo

BCYC
Bicycle Therapeutics Plc - ADR

928
Mkt Cap
$252.15M
Volume
325,064.00
52W High
$9.55
52W Low
$4.24
PE Ratio
-1.59
BCYC Fundamentals
Price
$5.05
Prev Close
$4.90
Open
$4.79
50D MA
$5.45
Beta
1.24
Avg. Volume
546,855.62
EPS (Annual)
-$3.17
P/B
0.57
Rev/Employee
$252,623.69
$120.63
Loading...
Loading...
News
all
press releases
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of "Hold" from Analysts
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) has received a consensus rating of "Hold" from the eleven brokerages that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold...
MarketBeat·15h ago
News Placeholder
More News
News Placeholder
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC)
Bicycle Therapeutics (BCYC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks·12d ago
News Placeholder
Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Bicycle Therapeutics (BCYC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks·13d ago
News Placeholder
Bicycle Therapeutics (NASDAQ:BCYC) Raised to Hold at Wall Street Zen
Wall Street Zen raised shares of Bicycle Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·16d ago
News Placeholder
Bicycle Therapeutics (NASDAQ:BCYC) Price Target Lowered to $36.00 at Oppenheimer
Oppenheimer decreased their target price on shares of Bicycle Therapeutics from $44.00 to $36.00 and set an "outperform" rating for the company in a research note on Wednesday...
MarketBeat·18d ago
News Placeholder
Bicycle Therapeutics (NASDAQ:BCYC) Given New $7.00 Price Target at Royal Bank Of Canada
Royal Bank Of Canada reduced their target price on shares of Bicycle Therapeutics from $11.00 to $7.00 and set a "sector perform" rating for the company in a report on Wednesday...
MarketBeat·18d ago
News Placeholder
Bicycle Therapeutics (NASDAQ:BCYC) Price Target Cut to $8.00 by Analysts at Citizens Jmp
Citizens Jmp reduced their price target on shares of Bicycle Therapeutics from $12.00 to $8.00 and set a "market outperform" rating on the stock in a research report on Wednesday...
MarketBeat·18d ago
News Placeholder
Bicycle Therapeutics (NASDAQ:BCYC) Price Target Lowered to $15.00 at Needham & Company LLC
Needham & Company LLC dropped their price target on shares of Bicycle Therapeutics from $24.00 to $15.00 and set a "buy" rating on the stock in a research report on Wednesday...
MarketBeat·18d ago
News Placeholder
Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today...
Business Wire·18d ago
News Placeholder
Bicycle Therapeutics (NASDAQ:BCYC) Issues Quarterly Earnings Results
Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.71...
MarketBeat·19d ago
<
1
2
...
>

Latest BCYC News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.